A multi-agent workflow converts CAR-T patient evidence into experimentally testable hypotheses
Wang, S.; Li, Y.-R.; Wang, Q.; Yang, Y.; Shen, X.; Li, H.; Nan, H.; Chen, Z.; Zhu, Y.; Zhang, B.; Ding, H.; Soto, J.; Park, S.; Zheng, Y.; Huang, X.; Yang, L.; Li, D.; Li, S.
Show abstract
The rapid expansion of chimeric antigen receptor (CAR) T cell studies has produced a fragmented evidence landscape linking publications, repository accessions, patient metadata and mechanistic observations. Here we present BioPathfinder, a multi-agent discovery engine for CAR-T research evidence construction, hypothesis generation and validation planning. Unlike existing LLM-based and agentic approaches centered on predefined CAR-T development tasks, BioPathfinder constructs a provenance-tracked resource linking scRNA-seq datasets from treated patients to their publications and uses it to generate diverse, falsifiable and dataset-aware mechanistic hypotheses prioritized for computational and experimental validation by role-specialized LLM reviewer subagents. Applied to the curated CAR-T-treated patient paper-dataset corpus, BioPathfinder nominated candidate mechanisms of CAR-T persistence, dysfunction and therapeutic resistance, including the hypothesis that genes associated with an NK-like transition program could be targeted to reduce CAR-T exhaustion and promote persistence. Patient scRNA-seq analysis showed that this NK-like transition-associated program was enriched in exhausted post-infusion CAR-T cell states. Virtual perturbation further prioritized transition-associated KLR-family receptor genes, including KLRC1, KLRD1 and KLRG1. Expert review selected KLRC1, encoding NKG2A, for experimental testing. In vitro and in vivo chronic-stimulation models showed that NKG2A marked CD8+ CAR-T cells with activated and exhaustion-associated phenotypes. NKG2A blockade improved antitumour function and persistence-associated readouts in vivo. These results show that structured clinical single-cell evidence can be transformed by domain-specialized multi-agent systems into experimentally actionable CAR-T engineering hypotheses. HighlightsO_LIBioPathfinder structures fragmented CAR-T patient evidence into a provenance-tracked paper-dataset resource. C_LIO_LIMulti-agent planning and review prioritize experimentally testable mechanisms of CAR-T dysfunction. C_LIO_LIExpert selection from BioPathfinder-nominated NK-like transition-associated genes identifies KLRC1/NKG2A blockade as a strategy to promote CAR-T persistence. C_LI
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors 97%
- Detection of isoforms and genomic alterations by high-throughput full-length single-cell RNA sequencing in ovarian cancer 97%
- Projecting single-cell transcriptomics data onto a reference T cell atlas to interpret immune responses 97%
Similar papers in this journal
- A new universal chimeric-antigen receptor (CAR)- fragment antibody binder (FAB) split system for cancer immunotherapy 96%
- Modulating immune cell fate and inflammation through CRISPR-mediated DNA methylation editing 96%
- Identification and Targeting of Regulators of SARS-CoV-2-Host Interactions in the Airway Epithelium. 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.